Screener
Viking Therapeutics VKTX Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Prepaid clinical trial and preclinical study costs | 4,021 | 8,053 |
| Prepaid expenses and other current assets | 1,224 | 1,806 |
| Total current assets | 608,209 | 715,598 |
| Right-of-use assets | — | 85 |
| Deposits | 33 | 46 |
| Total assets | $608,242 | $715,729 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's operating lease ROU assets?
- Viking Therapeutics (VKTX) reported operating lease ROU assets of $0 in Q1 2026.
- How has Viking Therapeutics's operating lease ROU assets changed year-over-year?
- Viking Therapeutics's operating lease ROU assets decreased by 100.0% year-over-year, from $892K to $0.
- What is the long-term trend for Viking Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), Viking Therapeutics's operating lease ROU assets has grown at a -23.3% compound annual growth rate (CAGR), from $321K to $85K.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Viking Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude